CRMD CorMedix Inc Common Stock

1.04
0  -6%
Previous Close 1.11
Open 1.10
Price To book 2.51
Market Cap 41.94M
Shares 40,323,000
Volume 272,475
Short Ratio 29.76
Av. Daily Volume 248,356

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be completed 2Q 2018. Data due end of 2018 with interim analysis possibly due 4Q 2017.
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 to be initiated pending funding.
Neutrolin - LOCK-IT 200
Oncology patients on Total Parental Nutrition (TPN)

Latest News

  1. CorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million
  2. CorMedix Inc. Announces $10 Million Underwritten Public Offering
  3. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CorMedix, Inc.
  4. CorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial
  5. CorMedix Inc. Secures First European Commercial Collaboration for Neutrolin(R)
  6. ETFs with exposure to CorMedix, Inc. : April 10, 2017
  7. Are Options Traders Betting on a Big Move in CorMedix (CRMD) Stock?
  8. CorMedix Inc. Makes NYSE MKT Section 610(b) Public Announcement
  9. CorMedix, Inc. :CRMD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  10. CorMedix's stock plunges after warning that it may run out of cash
  11. CorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  12. CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update
  13. CorMedix Inc. Appoints John L. (Jack) Armstrong to Senior Leadership Team
  14. CorMedix Inc. Announces New Appointments to Senior Leadership Team
  15. ETFs with exposure to CorMedix, Inc. : January 19, 2017
  16. Is the Options Market Predicting a Spike in CorMedix (CRMD) Stock?
  17. CorMedix Inc. Announces Dismissal of Shareholder Derivative Action Lawsuit and Stipulation to Forego Appeal
  18. CorMedix to Present at Biotech Showcase 2017
  19. CorMedix Inc. Announces Dismissal of Securities Class Action Lawsuit and Stipulation to Forego Appeal